IBCSG 12-93

  • Tamoxifen for 5 years vs. toremifene for 5 years with or without chemotherapy as adjuvant therapy for post/perimenopausal, node positive, hormone receptor positive breast cancer patients.

  • Study Chairs
    Dr. Olivia Pagani - Mendrisio, Switzerland
    Dr. Edda Simoncini - Brescia, Italy

    Statistician
    Shari Gelber

    Director of the Data Management Center
    Holly Shaw

    IBCSG Data Management Center/FSTRF
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email:     This email address is being protected from spambots. You need JavaScript enabled to view it.


    Date of Activation
    May 1, 1993

    Date of Closure
    August 1, 1999

    Targeted Accrual
    960 patients

    Final Accrual
    452 patients

    Date of Discontinued Follow-up
    December 31, 2010

ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org

Member Login